Retina/Vitreous News

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Kelley Sheets of Eyedaptic gives an overview of the Eye6 wearable vision aid for patients with age-related macular degeneration.

Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.

A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic macular edema in clinical practice guidelines.

In this Healio Video Perspective from the ASRS meeting, Eleonora M. Lad, MD, PhD, of Duke University Medical Center discusses findings from the phase 2 ARCHER trial investigating ANX007 for geographic atrophy.

The FDA granted rare pediatric disease designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

Vitreoretinal surgery fellows tend to become faster at peeling over the course of their fellowship, according to a study presented at the American Society of Retina Specialists annual meeting.

In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.

Healio spoke with Bradley Dougherty, OD, PhD, associate professor at The Ohio State University College of Optometry, about how socioeconomic factors can affect the diagnosis, treatment and outcomes of age-related macular degeneration.

A questionnaire found that the majority of retina fellows planned to go into a retina-only private practice.

Eclipse Life Sciences has enrolled and dosed the first patient in the BETTIS-1 phase 2 clinical trial investigating the EC-104 implant for the treatment of diabetic macular edema, according to a press release.